Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose MK-2060 safety, PK and PD in Japanese older participants with ESRD on dialysis
jRCT2041230025Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in end-stage kidney disease (ESKD) comparing MK-2060 50 mg IV with Placebo IV (2 arms). Primary endpoints: Number of Participants Who Experience an Adverse Event (AE) and Number of Participants Who Discontinue Study Due to an AE. Started Jun 2023; status: completed.
02
Drugs
MK-2060
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCT2041230025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230025.